Daewoong Pharmaceutical’s Nabota Advances into Brazil, the Largest Market in Latin America, with Marketing Authorization

Daewoong Pharmaceutical’s Nabota Advances into Brazil, the Largest Market in Latin America, with Marketing Authorization - Expected to see fast growth for both cosmetic and treatment indications simultaneously with marketing authorization - Marketing authorization acquired from 51 countries worldwide as well as sales agreements signed with about 80 countries Nabota, a proprietary botulinum toxin product of Daewoong Pharmaceutical, is making foray into the Latin American market. Daewoong Pharmaceutical (CEO Sengho Jeon) announced on March 20 that it has obtained marketing authorization for Nabota in Brazil, the largest market in Latin America on March 17 (local time). The Brazilian National Sanitary Surveillance Agency (Agência Nacional de Vigilância Sanitária; ANVISA) approved marketing authorization for Nabota’s indication of improving glabellar wrinkles and treating upper limb spasticity after stroke. Nabota has currently obtained marketing authorization in nine Latin American countries including Mexico, Panama and Bolivia, and is planning to further solidify its position in the Latin American market by entering Brazil, the largest market in Latin America, with this newly acquired marketing authorization. Daewoong Pharmaceutical is planning to ship the first exports to Brazil in the first half of this year, and its partner Moksha8 will sell Nabota in Brazil. Moksha8 is a professional pharmaceutical company with experience in successfully selling various global pharmaceutical products, including for the digestive, cardiovascular and central nervous systems, and has a network of hospitals and clinics covering all across Brazil. While Moksha8 will be directly responsible for the sales of Nabota as a treatment drug, Daewoong is planning to partner with another professional company to target the plastic surgery/cosmetics market. Seongsoo Park, head of NABOTA Operations, said, “In Brazil’s botulinum toxin market, the treatment market is as large as the cosmetics market. As Nabota obtained market authorization for both cosmetics and treatment indications, we are expecting that it can grow fast in this local market.” Meanwhile, this botulinum toxin product originally manufactured and supplied by Daewoong has obtained marketing authorization in 51 countries worldwide including the US, Canada and Europe, and sales agreements has been signed with about 80 countries. #   #   # [Photograph courtesy of Daewoong Pharmaceutical] Daewoong Pharmaceutical’s proprietary botulinum toxin product Nabota obtains market authorization in Brazil, the largest market in Latin America.

The release as fetched from its publisher. daewoong.co.kr ↗